iodixanol has been researched along with Neoplasms in 3 studies
iodixanol: dimeric contrast media; structure given in first source
iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the incidence of post-contrast acute kidney injury (PC-AKI) and presumed contrast-induced acute kidney injury (CI-AKI) following contrast-enhanced CT (CECT) with intravenous application of a reduced dose of the iso-osmolar contrast agent iodixanol in cancer patients with chronic kidney disease." | 7.96 | Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol. ( Bez, C; Hinterleitner, C; Horger, M; Werner, S, 2020) |
| "To determine the incidence of post-contrast acute kidney injury (PC-AKI) and presumed contrast-induced acute kidney injury (CI-AKI) following contrast-enhanced CT (CECT) with intravenous application of a reduced dose of the iso-osmolar contrast agent iodixanol in cancer patients with chronic kidney disease." | 3.96 | Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol. ( Bez, C; Hinterleitner, C; Horger, M; Werner, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Werner, S | 1 |
| Bez, C | 1 |
| Hinterleitner, C | 1 |
| Horger, M | 1 |
| Terrenato, I | 1 |
| Sperati, F | 1 |
| Musicco, F | 1 |
| Pozzi, AF | 1 |
| di Turi, A | 1 |
| Caterino, M | 1 |
| de Lutio di Castelguidone, E | 1 |
| Setola, SV | 1 |
| Bellomi, M | 1 |
| Neumaier, CE | 1 |
| Conti, L | 1 |
| Cigliana, G | 1 |
| Merola, R | 1 |
| Antenucci, A | 1 |
| Orlandi, G | 1 |
| Giordano, A | 1 |
| Barba, M | 1 |
| Canitano, S | 1 |
| Xu, H | 1 |
| Ohulchanskyy, TY | 1 |
| Yakovliev, A | 1 |
| Zinyuk, R | 1 |
| Song, J | 1 |
| Liu, L | 1 |
| Qu, J | 1 |
| Yuan, Z | 1 |
1 trial available for iodixanol and Neoplasms
| Article | Year |
|---|---|
Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Contrast Media; Female; Glomerular Filtration Rate; Humans; Iohexol; Italy; | 2018 |
2 other studies available for iodixanol and Neoplasms
| Article | Year |
|---|---|
Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Contrast Media; Female; Humans; Incidence; Male | 2020 |
Nanoliposomes Co-Encapsulating CT Imaging Contrast Agent and Photosensitizer for Enhanced, Imaging Guided Photodynamic Therapy of Cancer.
Topics: Animals; Cell Line, Tumor; Cell Survival; Contrast Media; Liposomes; Mice, Inbred BALB C; Mice, Nude | 2019 |